FDA Panel Recommends Pulling Preterm Birth Drug From the Market

FDA Panel Recommends Pulling Preterm Birth Drug From the Market

The New York Times - Business:

The agency has weighed years of study that showed the treatment given accelerated approval 11 years ago was not effective.

This post first appeared in The New York Times - Business. Read the original article.